छोड़कर सामग्री पर जाएँ

Divi#39;s Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill

Divi#39;s Laboratories is likely to report a slump in its Q4 earnings on a year-on-year basis. However, sequentially, the drugmaker may see some modest recovery in its financials.

Read More

​ Divi#39;s Laboratories is likely to report a slump in its Q4 earnings on a year-on-year basis. However, sequentially, the drugmaker may see some modest recovery in its financials. Divi#39;s Laboratories is likely to report a slump in its Q4 earnings on a year-on-year basis. However, sequentially, the drugmaker may see some modest recovery in its financials.  Moneycontrol Latest News Read More  

प्रातिक्रिया दे

आपका ईमेल पता प्रकाशित नहीं किया जाएगा. आवश्यक फ़ील्ड चिह्नित हैं *

hi_INहिन्दी